Qianben Wang Laboratory: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
No edit summary |
No edit summary |
||
Line 18: | Line 18: | ||
<table border="4" color="mediumblue"> | <table border="4" color="mediumblue"> | ||
<td width="926"> | <td width="926"> | ||
[[Image: | [[Image:exo.tif]] | ||
<div style="text-align:left" font face="lucia fax">''' | <div style="text-align:left" font face="lucia fax">'''The schematic diagram of androgen receptor binding element (ARBE)-directed AR transcriptional regulation. Upper panel shows that agonist-bound AR (red) recognizes an agonist-ARBE in an agonist-specific manner, whereas the bottom panel indicates that antagonist-bound AR (blue) binds to an antagonist-ARBE in an antagonist-dependent manner. The binding of AR to two distinctly different motifs leads to distinct transcriptional outcomes in prostate cancer. The crystal structures of the DNA binding domain (DBD), dihydrotestosterone-ligand binding domain (DHT-LBD) and bicalutamide-LBD are modified from 1R4I, 1T7T and 1Z95, respectively. | ||
</div> | </div> | ||
</td> | </td> | ||
</table> | </table> |
Revision as of 14:08, 23 December 2014
The schematic diagram of androgen receptor binding element (ARBE)-directed AR transcriptional regulation. Upper panel shows that agonist-bound AR (red) recognizes an agonist-ARBE in an agonist-specific manner, whereas the bottom panel indicates that antagonist-bound AR (blue) binds to an antagonist-ARBE in an antagonist-dependent manner. The binding of AR to two distinctly different motifs leads to distinct transcriptional outcomes in prostate cancer. The crystal structures of the DNA binding domain (DBD), dihydrotestosterone-ligand binding domain (DHT-LBD) and bicalutamide-LBD are modified from 1R4I, 1T7T and 1Z95, respectively.
|